Connect with us
Florida-based psychedelics firm Enveric Biosciences (NASDAQ: ENVB), which is still in the pre-revenue stage, this week reported a $9.5 million net loss for 2024, down from...
Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) said Friday it’s made some inroads with its financials in 2024, removing its going concern designation as...
Relmada Therapeutics (Nasdaq: RLMD) announced Thursday it was shifting away from its previous focus on depression treatments and psychedelics, after acquiring two new Phase 2 drug...
A study testing a low-dosage LSD treatment for adult attention-deficit/hyperactivity disorder (ADHD) didn’t pan out as planned. A new article in JAMA (Journal of American Medical...
New Mexico could become the third state in the country to legalize access to psilocybin if the Governor signs the proposed legislation. S.B. 219 also known...
PharmAla Biotech Holdings Inc. (CSE: MDMA) (OTC: MDXXF) announced that it has contracted with a third-party logistics company specializing in pharmaceutical products to act as its...
Alto Neuroscience, Inc. (NYSE: ANRO) reported financial results for the full year ending December 31, 2024, highlighting recent progress across its pipeline of clinical-stage product candidates....
